Krystal Biotech (KRYS) Q3 2025 earnings summary

Executive summary

• Achieved $97.8 million in VYJUVEK net product revenue in Q3 2025, with gross margin of 96% and strong early demand in Europe and Japan.

• Net income for Q3 2025 was $79.4 million, up from $27.2 million in Q3 2024, reflecting higher sales, improved margin, and a one-time tax benefit.

• Expanded VYJUVEK launches to Germany, France, and Japan, with ongoing payer negotiations and early access in France.

• Pipeline advanced with new clinical programs and near-term readouts expected in respiratory, oncology, ophthalmology, dermatology, and aesthetics.

• FDA granted platform technology designation for HSV-1 vector platform, supporting future pipeline acceleration.

Financial highlights

• Q3 2025 product revenue: $97.8M (up from $83.8M in Q3 2024); nine months ended September 30, 2025: $282.0M (up from $199.4M in 2024).

• Gross margin for Q3 2025 was 96%, up from 92% in Q3 2024, due to manufacturing optimizations.

• Net income for Q3 2025: $79.4M (EPS basic $2.74, diluted $2.66); nine months: $153.4M (EPS basic $5.31, diluted $5.14).

• Cash and investments totaled $864.2M as of September 30, 2025.

• R&D expenses: $14.6M; SG&A expenses: $37.6M; non-cash stock-based compensation: $13.2M.

Outlook and guidance

• Expect continued steady growth in European patient inclusion and modest initial contribution from Japan, with greater impact in 2026.

• No full-year revenue guidance for 2026 due to multiple ongoing launches and evolving distribution.

• Revised full-year non-GAAP R&D and SG&A guidance to $145–$155 million, excluding stock-based compensation.

• Interim results for cystic fibrosis program (KB407) expected in Q4 2025.

• Cash position sufficient to fund operations for at least 12 months from the filing date.